

Delpazolid

Catalog No: tcsc0018175



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1219707-39-7

Formula:

$C_{14}H_{17}FN_4O_3$

Pathway:

Anti-infection

Target:

Bacterial

Purity / Grade:

>98%

Solubility:

DMSO : 30 mg/mL (97.30 mM; Need ultrasonic and warming)

Alternative Names:

LCB01-0371

Observed Molecular Weight:

308.31


Product Description

Delpazolid is a novel oxazolidinone antibiotic agent which can inhibit the growth of **MSSA** and **MRSA** with a **MIC₉₀** of 2 µg/mL for both of them.

IC50 & Target: MIC90: 2 µg/mL (MSSA), 2 µg/mL (MRSA)^[1]

In Vitro: Delpazolid (LCB01-0371), at concentrations of 1×MIC and 2×MIC, has bacteriostatic activity against MSSA and MRSA after 24 h. At concentrations of 4×MIC and 8×MIC, Delpazolid shows bacteriostatic activity, but there is no regrowth at concentrations of 4×MIC and 8×MIC after 24 h of incubation^[1]. The survival of *M. abscessus* is greatly decreased in the presence of Delpazolid (LCB-0371) (MIC₅₀=1.2 µg/mL). Delpazolid dramatically decreases the number of intracellular mycobacteria present at 2 days after infection at concentrations of 0.1, 1, and 10 µg/mL^[2].

In Vivo: When administered orally, Delpazolid (LCB01-0371) shows potent protective effects against systemic infections caused by Gram-positive and Gram-negative bacteria. Against infection caused by *S. aureus* Giorgio (MSSA), the ED₅₀ of Delpazolid is 4.53 mg/kg of body weight. Against *S. aureus* p125 (MRSA), the ED₅₀ of Delpazolid is 2.96 mg/kg^[1]. When Delpazolid (LCB-0371) is administered at 100 mg/kg daily (by gavage), the colony-forming unit (CFU) counts tend to be decreased in the lungs of mice at 7 days after infection^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!